NCT00474929 - Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | Biotech Hunter

Enrollment

103

Participants

Timeline

Start Date

August 29, 2007

Primary Completion Date

November 5, 2011

Study Completion Date

August 8, 2019

Conditions

LymphomaMultiple Myeloma and Plasma Cell Neoplasm

Interventions

DRUG

RAD001

Phase I: Dose level 0: RAD001 5mg every other day; Dose level 1: RAD001 5mg every day; Dose level 2: RAD001 5mg every day; Dose level 3: RAD001 10mg every day; Phase II: RAD001 5mg every day;

DRUG

Sorafenib

Phase I: Dose level 0: Sorafenib 200 mg twice daily; Dose level 1: Sorafenib 200 mg twice daily; Dose level 2: Sorafenib 400 mg twice daily; Dose level 3: Sorafenib 400 mg twice daily; Phase II: Sorafenib 200 mg twice daily;

Trial Locations (2)

55905

Mayo Clinic Cancer Center, Rochester

52242-1002

Holden Comprehensive Cancer Center at University of Iowa, Iowa City